Dagglitazin is a sodium glucose cotransporter 2 inhibitor (sglt2i), which is a new oral hypoglycemic drug. It can inhibit SGLT2 activity, inhibit sodium glucose reabsorption in proximal renal tubules, promote urinary glucose excretion, and reduce blood glucose concentration.